PURPOSE OF REVIEW: It is increasingly clear that asthma is not a single disease, but a disorder with vast heterogeneity in pathogenesis, severity, and treatment response. In this review, we discuss the present understanding of different asthma phenotypes and endotypes, and the prospects of personalized medicine for asthma. RECENT FINDINGS: The recognition of diverse biological backgrounds in which asthma, and particularly severe asthma, can manifest has prompted the search for refined phenotypes and endotypes in asthma. Such appreciation of the heterogeneity in asthma is also prompting clinical trials to focus on specific subgroups of asthma, as demonstrated by the clinical trial of lebrikizumab. SUMMARY: Patients with severe asthma have asthma symptoms that are difficult to control, require high dosages of medication, and continue to experience persistent symptoms, asthma exacerbations or airflow obstruction even with aggressive therapy. Although asthma is traditionally viewed as an eosinophilic inflammatory disorder associated with a T-helper cell type 2 (Th2) immune response, recent studies have identified involvement of other effector cells, nonclassical Th2 cytokines and non-Th2 cytokines in severe asthma pathogenesis. Results of several clinical trials of anticytokine antibodies demonstrated the effectiveness of tailoring asthma treatment on the basis of an individual's biology.
PURPOSE OF REVIEW: It is increasingly clear that asthma is not a single disease, but a disorder with vast heterogeneity in pathogenesis, severity, and treatment response. In this review, we discuss the present understanding of different asthma phenotypes and endotypes, and the prospects of personalized medicine for asthma. RECENT FINDINGS: The recognition of diverse biological backgrounds in which asthma, and particularly severe asthma, can manifest has prompted the search for refined phenotypes and endotypes in asthma. Such appreciation of the heterogeneity in asthma is also prompting clinical trials to focus on specific subgroups of asthma, as demonstrated by the clinical trial of lebrikizumab. SUMMARY:Patients with severe asthma have asthma symptoms that are difficult to control, require high dosages of medication, and continue to experience persistent symptoms, asthma exacerbations or airflow obstruction even with aggressive therapy. Although asthma is traditionally viewed as an eosinophilic inflammatory disorder associated with a T-helper cell type 2 (Th2) immune response, recent studies have identified involvement of other effector cells, nonclassical Th2 cytokines and non-Th2 cytokines in severe asthma pathogenesis. Results of several clinical trials of anticytokine antibodies demonstrated the effectiveness of tailoring asthma treatment on the basis of an individual's biology.
Authors: T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie Journal: Clin Rev Allergy Immunol Date: 2015-02 Impact factor: 8.667
Authors: L F Loffredo; H Abdala-Valencia; K R Anekalla; L Cuervo-Pardo; C J Gottardi; S Berdnikovs Journal: Allergy Date: 2017-07-06 Impact factor: 13.146
Authors: Caroline M Percopo; Kimberly D Dyer; Sergei I Ochkur; Janice L Luo; Elizabeth R Fischer; James J Lee; Nancy A Lee; Joseph B Domachowske; Helene F Rosenberg Journal: Blood Date: 2013-12-02 Impact factor: 22.113
Authors: Sang Heon Kim; Ji Yong Moon; Jae Hyun Lee; Ga Young Ban; Sujeong Kim; Mi Ae Kim; Joo Hee Kim; Min Hye Kim; Chan Sun Park; So Young Park; Hyouk Soo Kwon; Jae Woo Kwon; Jae Woo Jung; Hye Ryun Kang; Jong Sook Park; Tae Bum Kim; Heung Woo Park; You Sook Cho; Kwang Ha Yoo; Yeon Mok Oh; Byung Jae Lee; An Soo Jang; Sang Heon Cho; Hae Sim Park; Choon Sik Park; Ho Joo Yoon Journal: Allergy Asthma Immunol Res Date: 2018-05 Impact factor: 5.764